Skip to main content
Normal View

Cannabis for Medicinal Use

Dáil Éireann Debate, Tuesday - 15 February 2022

Tuesday, 15 February 2022

Questions (148)

Gino Kenny

Question:

148. Deputy Gino Kenny asked the Minister for Health if he will support broadening the range of products considered as suitable for use under the Medical Cannabis Access Programme in the context of the ongoing scientific review of cannabis for medical use; and if he will make a statement on the matter. [7944/22]

View answer

Written answers (Question to Health)

In the Misuse of Drugs (Prescription and Control of Supply of Cannabis for Medical Use) Regulations 2019 (S.I. 262/2019) the definition of ‘specified controlled drugs’ describes the cannabis product or preparation that can be used in the Medical Cannabis Access Programme and the specific requirements for those products.

A prospective supplier can apply to the Health Products Regulatory Authority (HPRA), on behalf of the Minister, to have a product considered for inclusion in the Schedule of ‘specified controlled drugs’ in the Regulations. As specified controlled drugs will fall under schedule 2 to the Misuse of Drugs Regulations 2017, a controlled drugs licence, processed by the HPRA, on behalf of the Minister, is also required for possession, supply or import of such cannabis products.

Details on how to apply for a licence to possess, supply or import medical cannabis products for use under the Medical Cannabis Access Programme in accordance with the requirements for schedule 2 products in the Misuse of Drugs Regulations 2017 can be found in the operator guidance issued by the HPRA.

It is open to any supplier or producer to apply to the HPRA to have their products assessed for inclusion in the programme.

Top
Share